Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes
Identifieur interne : 001809 ( Istex/Corpus ); précédent : 001808; suivant : 001810Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes
Auteurs : Ana M. Catafau ; Eduardo TolosaSource :
- Movement Disorders [ 0885-3185 ] ; 2004-10.
English descriptors
- KwdEn :
- Teeft :
- Abnormal, Abnormal type, Adverse events, Amersham health, Arch neurol, Atypical signs, Catafau, Caudate nucleus, Causal relationship, Challenge test, Clinical data, Clinical diagnosis, Clinical impact, Clinical management, Cocaine recognition sites, Degeneration, Diagnosis, Dopamine, Dopamine transporter, Dopaminergic, Eduardo tolosa, Essential tremor, Focal dystonia, Further investigations, Gamma cameras, High sensitivity, Imaging, Imaging result, Inconclusive, Initial diagnosis, Mild intensity, Movement disorders, Movement disorders unit, Neurol, Neurol neurosurg psychiatry, Neurologist, Neurology service, Nigrostriatal, Nigrostriatal degeneration, Nonpresynaptic, Normal scan, Normal striatal uptake, Parkinsonian, Parkinsonism, Patient management, Presynaptic, Primary somatosensory cortex, Processing protocols, Rest tremor, Severe depletion, Spect, Spect image, Spect images, Spect imaging, Spect results, Striatal, Striatal uptake, Syndrome, Therapeutic intervention, Transporter, Tremor, Uncertain parkinsonian syndromes, Uncertain parkinsonism, Visit intervals, Visual assessment.
Abstract
Imaging with 123I‐Ioflupane single‐photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS]) from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of 123I‐Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20112
Links to Exploration step
ISTEX:E7ABB9D951538A49EF1C2F044D076C52242A6699Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes</title><author><name sortKey="Catafau, Ana M" sort="Catafau, Ana M" uniqKey="Catafau A" first="Ana M." last="Catafau">Ana M. Catafau</name><affiliation><mods:affiliation>Institut de Recerca, Hospital de Sant Pau, Barcelona, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Current Address: Centre for Imaging in Psychiatry, Clinical Pharmacology Discovery Medicine, Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic, c/ Villarroel, 170, 08036, Barcelona, Spain</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E7ABB9D951538A49EF1C2F044D076C52242A6699</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20112</idno><idno type="url">https://api.istex.fr/document/E7ABB9D951538A49EF1C2F044D076C52242A6699/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001809</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001809</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes</title><author><name sortKey="Catafau, Ana M" sort="Catafau, Ana M" uniqKey="Catafau A" first="Ana M." last="Catafau">Ana M. Catafau</name><affiliation><mods:affiliation>Institut de Recerca, Hospital de Sant Pau, Barcelona, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Current Address: Centre for Imaging in Psychiatry, Clinical Pharmacology Discovery Medicine, Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic, c/ Villarroel, 170, 08036, Barcelona, Spain</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-10">2004-10</date><biblScope unit="volume">19</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1175">1175</biblScope><biblScope unit="page" to="1182">1182</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E7ABB9D951538A49EF1C2F044D076C52242A6699</idno><idno type="DOI">10.1002/mds.20112</idno><idno type="ArticleID">MDS20112</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>123I‐Ioflupane</term><term>SPECT</term><term>dopamine transporter</term><term>parkinsonism</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Abnormal</term><term>Abnormal type</term><term>Adverse events</term><term>Amersham health</term><term>Arch neurol</term><term>Atypical signs</term><term>Catafau</term><term>Caudate nucleus</term><term>Causal relationship</term><term>Challenge test</term><term>Clinical data</term><term>Clinical diagnosis</term><term>Clinical impact</term><term>Clinical management</term><term>Cocaine recognition sites</term><term>Degeneration</term><term>Diagnosis</term><term>Dopamine</term><term>Dopamine transporter</term><term>Dopaminergic</term><term>Eduardo tolosa</term><term>Essential tremor</term><term>Focal dystonia</term><term>Further investigations</term><term>Gamma cameras</term><term>High sensitivity</term><term>Imaging</term><term>Imaging result</term><term>Inconclusive</term><term>Initial diagnosis</term><term>Mild intensity</term><term>Movement disorders</term><term>Movement disorders unit</term><term>Neurol</term><term>Neurol neurosurg psychiatry</term><term>Neurologist</term><term>Neurology service</term><term>Nigrostriatal</term><term>Nigrostriatal degeneration</term><term>Nonpresynaptic</term><term>Normal scan</term><term>Normal striatal uptake</term><term>Parkinsonian</term><term>Parkinsonism</term><term>Patient management</term><term>Presynaptic</term><term>Primary somatosensory cortex</term><term>Processing protocols</term><term>Rest tremor</term><term>Severe depletion</term><term>Spect</term><term>Spect image</term><term>Spect images</term><term>Spect imaging</term><term>Spect results</term><term>Striatal</term><term>Striatal uptake</term><term>Syndrome</term><term>Therapeutic intervention</term><term>Transporter</term><term>Tremor</term><term>Uncertain parkinsonian syndromes</term><term>Uncertain parkinsonism</term><term>Visit intervals</term><term>Visual assessment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Imaging with 123I‐Ioflupane single‐photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS]) from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of 123I‐Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients. © 2004 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>spect</json:string><json:string>presynaptic</json:string><json:string>parkinsonism</json:string><json:string>spect imaging</json:string><json:string>nonpresynaptic</json:string><json:string>parkinsonian</json:string><json:string>clinical diagnosis</json:string><json:string>nigrostriatal</json:string><json:string>striatal</json:string><json:string>dopamine</json:string><json:string>imaging</json:string><json:string>uncertain parkinsonian syndromes</json:string><json:string>transporter</json:string><json:string>nigrostriatal degeneration</json:string><json:string>spect images</json:string><json:string>neurol</json:string><json:string>dopaminergic</json:string><json:string>catafau</json:string><json:string>movement disorders</json:string><json:string>essential tremor</json:string><json:string>spect image</json:string><json:string>visual assessment</json:string><json:string>neurologist</json:string><json:string>initial diagnosis</json:string><json:string>patient management</json:string><json:string>normal striatal uptake</json:string><json:string>abnormal type</json:string><json:string>clinical management</json:string><json:string>adverse events</json:string><json:string>degeneration</json:string><json:string>syndrome</json:string><json:string>abnormal</json:string><json:string>challenge test</json:string><json:string>dopamine transporter</json:string><json:string>rest tremor</json:string><json:string>visit intervals</json:string><json:string>clinical data</json:string><json:string>striatal uptake</json:string><json:string>diagnosis</json:string><json:string>tremor</json:string><json:string>inconclusive</json:string><json:string>severe depletion</json:string><json:string>neurology service</json:string><json:string>primary somatosensory cortex</json:string><json:string>focal dystonia</json:string><json:string>atypical signs</json:string><json:string>mild intensity</json:string><json:string>amersham health</json:string><json:string>cocaine recognition sites</json:string><json:string>neurol neurosurg psychiatry</json:string><json:string>clinical impact</json:string><json:string>uncertain parkinsonism</json:string><json:string>causal relationship</json:string><json:string>normal scan</json:string><json:string>eduardo tolosa</json:string><json:string>gamma cameras</json:string><json:string>processing protocols</json:string><json:string>caudate nucleus</json:string><json:string>movement disorders unit</json:string><json:string>imaging result</json:string><json:string>spect results</json:string><json:string>further investigations</json:string><json:string>therapeutic intervention</json:string><json:string>arch neurol</json:string><json:string>high sensitivity</json:string></teeft></keywords><author><json:item><name>Ana M. Catafau MD</name><affiliations><json:string>Institut de Recerca, Hospital de Sant Pau, Barcelona, Spain</json:string><json:string>Current Address: Centre for Imaging in Psychiatry, Clinical Pharmacology Discovery Medicine, Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline</json:string></affiliations></json:item><json:item><name>Eduardo Tolosa MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain</json:string><json:string>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic, c/ Villarroel, 170, 08036, Barcelona, Spain</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>parkinsonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>123I‐Ioflupane</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine transporter</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>SPECT</value></json:item></subject><articleId><json:string>MDS20112</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Imaging with 123I‐Ioflupane single‐photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS]) from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of 123I‐Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients. © 2004 Movement Disorder Society</abstract><qualityIndicators><score>6.009</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1007</abstractCharCount><pdfWordCount>4341</pdfWordCount><pdfCharCount>28623</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>139</abstractWordCount></qualityIndicators><title>Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes</title><genre><json:string>article</json:string></genre><host><title>Movement Disorders</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi><issn><json:string>0885-3185</json:string></issn><eissn><json:string>1531-8257</json:string></eissn><publisherId><json:string>MDS</json:string></publisherId><volume>19</volume><issue>10</issue><pages><first>1175</first><last>1182</last><total>8</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Brief Report</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string><json:string>endocrinopathies</json:string></inist></categories><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><doi><json:string>10.1002/mds.20112</json:string></doi><id>E7ABB9D951538A49EF1C2F044D076C52242A6699</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/E7ABB9D951538A49EF1C2F044D076C52242A6699/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/E7ABB9D951538A49EF1C2F044D076C52242A6699/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E7ABB9D951538A49EF1C2F044D076C52242A6699/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Copyright © 2004 Movement Disorder Society</p></availability><date>2004</date></publicationStmt><notesStmt><note type="content">*Members of The DaTSCAN CUPS Study Group are listed in Appendix.</note><note>Amersham Health</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes</title><author xml:id="author-1"><persName><forename type="first">Ana M.</forename><surname>Catafau</surname></persName><roleName type="degree">MD</roleName><affiliation>Institut de Recerca, Hospital de Sant Pau, Barcelona, Spain</affiliation><affiliation>Current Address: Centre for Imaging in Psychiatry, Clinical Pharmacology Discovery Medicine, Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline</affiliation></author><author xml:id="author-2"><persName><forename type="first">Eduardo</forename><surname>Tolosa</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain</affiliation><affiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic, c/ Villarroel, 170, 08036, Barcelona, Spain</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-10"></date><biblScope unit="volume">19</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1175">1175</biblScope><biblScope unit="page" to="1182">1182</biblScope></imprint></monogr><idno type="istex">E7ABB9D951538A49EF1C2F044D076C52242A6699</idno><idno type="DOI">10.1002/mds.20112</idno><idno type="ArticleID">MDS20112</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2004</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Imaging with 123I‐Ioflupane single‐photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS]) from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of 123I‐Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients. © 2004 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>parkinsonism</term></item><item><term>123I‐Ioflupane</term></item><item><term>dopamine transporter</term></item><item><term>SPECT</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2003-06-05">Received</change><change when="2004-01-19">Registration</change><change when="2004-10">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/E7ABB9D951538A49EF1C2F044D076C52242A6699/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="100"><doi origin="wiley" registered="yes">10.1002/mds.v19:10</doi><numberingGroup><numbering type="journalVolume" number="19">19</numbering><numbering type="journalIssue">10</numbering></numberingGroup><coverDate startDate="2004-10">October 2004</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="60" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20112</doi><idGroup><id type="unit" value="MDS20112"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Report</title></titleGroup><copyright ownership="thirdParty">Copyright © 2004 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2003-06-05"></event><event type="manuscriptRevised" date="2003-11-14"></event><event type="manuscriptAccepted" date="2004-01-19"></event><event type="publishedOnlineEarlyUnpaginated" date="2004-04-22"></event><event type="firstOnline" date="2004-04-22"></event><event type="publishedOnlineFinalForm" date="2004-09-29"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1175</numbering><numbering type="pageLast">1182</numbering></numberingGroup><correspondenceTo>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic, c/ Villarroel, 170, 08036, Barcelona, Spain</correspondenceTo><objectNameGroup><objectName elementName="appendix">APPENDIX</objectName></objectNameGroup><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20112.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="5"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="18"></count><count type="wordTotal" number="4641"></count></countGroup><titleGroup><title type="main" xml:lang="en">Impact of dopamine transporter SPECT using <sup>123</sup>I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes<link href="#fn1"></link></title><title type="short" xml:lang="en">DAT SPECT in Uncertain Parkinsonian Syndromes</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" currentRef="#curr1"><personName><givenNames>Ana M.</givenNames><familyName>Catafau</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2" corresponding="yes"><personName><givenNames>Eduardo</givenNames><familyName>Tolosa</familyName><degrees>MD</degrees></personName><contactDetails><email>etolosa@clinic.ub.es</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="ES" type="organization"><unparsedAffiliation>Institut de Recerca, Hospital de Sant Pau, Barcelona, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="ES" type="organization"><unparsedAffiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain</unparsedAffiliation></affiliation><affiliation xml:id="curr1"><unparsedAffiliation>Centre for Imaging in Psychiatry, Clinical Pharmacology Discovery Medicine, Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">parkinsonism</keyword><keyword xml:id="kwd2"><sup>123</sup>I‐Ioflupane</keyword><keyword xml:id="kwd3">dopamine transporter</keyword><keyword xml:id="kwd4">SPECT</keyword></keywordGroup><fundingInfo><fundingAgency>Amersham Health</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Imaging with <sup>123</sup>I‐Ioflupane single‐photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS]) from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of <sup>123</sup>I‐Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients. © 2004 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Members of The DaTSCAN CUPS Study Group are listed in Appendix.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>DAT SPECT in Uncertain Parkinsonian Syndromes</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes</title></titleInfo><name type="personal"><namePart type="given">Ana M.</namePart><namePart type="family">Catafau</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Institut de Recerca, Hospital de Sant Pau, Barcelona, Spain</affiliation><affiliation>Current Address: Centre for Imaging in Psychiatry, Clinical Pharmacology Discovery Medicine, Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eduardo</namePart><namePart type="family">Tolosa</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain</affiliation><affiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic, c/ Villarroel, 170, 08036, Barcelona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2004-10</dateIssued><dateCaptured encoding="w3cdtf">2003-06-05</dateCaptured><dateValid encoding="w3cdtf">2004-01-19</dateValid><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">5</extent><extent unit="tables">2</extent><extent unit="references">18</extent><extent unit="words">4641</extent></physicalDescription><abstract lang="en">Imaging with 123I‐Ioflupane single‐photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS]) from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of 123I‐Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients. © 2004 Movement Disorder Society</abstract><note type="content">*Members of The DaTSCAN CUPS Study Group are listed in Appendix.</note><note type="funding">Amersham Health</note><subject lang="en"><genre>keywords</genre><topic>parkinsonism</topic><topic>123I‐Ioflupane</topic><topic>dopamine transporter</topic><topic>SPECT</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>1175</start><end>1182</end><total>8</total></extent></part></relatedItem><identifier type="istex">E7ABB9D951538A49EF1C2F044D076C52242A6699</identifier><identifier type="DOI">10.1002/mds.20112</identifier><identifier type="ArticleID">MDS20112</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2004 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sarre/explor/MusicSarreV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001809 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001809 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sarre
|area= MusicSarreV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:E7ABB9D951538A49EF1C2F044D076C52242A6699
|texte= Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes
}}
| This area was generated with Dilib version V0.6.33. |  |